SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Brainstorm Cell Therapeutics Inc. – ‘424B3’ on 6/26/20

On:  Friday, 6/26/20, at 5:02pm ET   ·   Accession #:  1104659-20-77518   ·   File #:  333-233349

Previous ‘424B3’:  ‘424B3’ on 6/26/20   ·   Next & Latest:  ‘424B3’ on 8/7/20

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 6/26/20  Brainstorm Cell Therapeutics Inc. 424B3                  1:13K                                    Toppan Merrill/FA

Prospectus – New Facts or Events   —   Rule 424(b)(3)
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 424B3       Prospectus - New Facts or Events                    HTML      9K 


This is an HTML Document rendered as filed.  [ Alternative Formats ]



  

Filed Pursuant to Rule 424(b)(3)

Registration Statement No. 333-233349

Prospectus Supplement No. 1

(to Prospectus dated August 30, 2019)

 

BRAINSTORM CELL THERAPEUTICS INC.

842,000 Shares of Common Stock

 

 

 

This prospectus supplement, together with the prospectus listed above, is to be used by certain holders of the above-referenced securities or by their pledgees, donees, transferees or other successors-in-interest in connection with the offer and sale of such securities.

 

This prospectus supplement updates and should be read in conjunction with the prospectus dated August 30, 2019 (as supplemented to date), which is to be delivered with this prospectus supplement. Such documents contain information that should be considered when making your investment decision. To the extent there is a discrepancy between the information contained herein and the information in the prospectus, the information contained herein supersedes and replaces such conflicting information.

 

This prospectus supplement consists of the below supplement to the Selling Securityholders of the prospectus.

 

Our common stock is traded on the Nasdaq Capital Market, under the symbol “BCLI”. On June 25, 2020, the last reported sales price for our common stock was $11.72 per share.

 

 

 

Investing in the Company’s securities involves risks. See “Risk Factors” beginning on page 4 of the Prospectus, as supplemented or amended by the prospectus supplements filed to date, to read about factors you should consider.

 

NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE ADEQUACY OR ACCURACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

 

 

 

The date of this Prospectus Supplement No. 1 is June 26, 2020

 

 C: 

 

 

 

The Selling Securityholders table on page 7 of the Prospectus is supplemented by including the following additional information:

 

   

Securities Beneficially

Owned
Prior to the Offering

  Securities Offered Hereby   Securities Beneficially
Owned
After this Offering
 

Percentage of
Common Stock
Owned After
this Offering

Name   Common
Stock
  Warrants   Common
Stock
  Common
Stock
underlying
Warrants
  Common
Stock
  Warrants    
Warberg WF VII LP     42,000**     42,000**       *

  

* Less than 1%

 

** Consists of Warrants assigned to Warberg WF VII LP, previously held by Selling Securityholder Warberg WF V LP.

 

 C: 

 

 


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘424B3’ Filing    Date    Other Filings
Filed on:6/26/204,  424B3,  8-K
6/25/20
8/30/194,  424B1,  EFFECT
 List all Filings 
Top
Filing Submission 0001104659-20-077518   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., Mar. 29, 3:12:50.1am ET